Coherus Oncology, Inc.
Commercial-stage biopharma developing immuno-oncology therapies for hard-to-treat cancers.
CHRS | US
Overview
Corporate Details
- ISIN(s):
- US19249H1032
- LEI:
- Country:
- United States of America
- Address:
- C/O DENNIS M. LANFEAR, 94065 REDWOOD CITY
- Website:
- https://www.coherus.com/
- Sector:
- Manufacturing
Description
Coherus Oncology, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing next-generation immuno-oncology (I-O) therapies. The company aims to transform cancer treatment and extend survival for patients with hard-to-treat tumors. Its portfolio is led by the FDA-approved anti-PD-1 monoclonal antibody LOQTORZI® (toripalimab-tpzi), a treatment for nasopharyngeal carcinoma. Coherus is advancing a diversified pipeline of clinical-stage drug candidates, concentrating on novel combination therapies that target the tumor microenvironment to improve patient outcomes.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Coherus Oncology, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Coherus Oncology, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Coherus Oncology, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
